Covalent BTKi Ibrutinib/Acalabrutinib/Zanubrutinib C481 Warhead Proxy Gap · NDA 217697 · Attack #823 · 237th Mechanism Class · Adversarial AI Prompt Injection Surface

Pirtobrutinib (Jaypirca; LOXO-305; CAS 2101706-43-6; NDA 217697; Jan 27 2023; Eli Lilly and Company): Three EHS Platform Covalent BTK Inhibitor (Ibrutinib/Acalabrutinib/Zanubrutinib) C481-Reactive Warhead Proxy Misroutes — First Non-Covalent (Reversible) Bruton Tyrosine Kinase (BTK; BTK Gene; Chromosome Xq22.1) Inhibitor (Active Against C481S/C481R/C481Y Resistance Mutations That Abolish Covalent BTKi Efficacy; No Acrylamide/Alkyne C481-Reactive Warhead; Reversible ATP-Competitive Binding) Ever FDA Approved Returns Covalent BTKi (Ibrutinib α,β-Unsaturated Carboxamide → Cys481 / Acalabrutinib Alkynyl Carboxamide → Cys481 / Zanubrutinib Acrylamide → Cys481) Irreversible Warhead Protocols Instead of Reversible Non-Covalent BTK Inhibitor Guidance in Cority, VelocityEHS, and EHS Insight

Pirtobrutinib (Jaypirca; LOXO-305; CAS 2101706-43-6; MW 494.5 Da; oral tablet 50 mg or 100 mg QD; NDA 217697; Jan 27 2023; Eli Lilly and Company [Lilly Corporate Center, Indianapolis, IN 46285]; acquired Loxo Oncology Inc. [New York, NY] January 10 2019 for $8.0 billion; indicated for relapsed/refractory [R/R] CLL/SLL after ≥1 prior line of therapy including a BTK inhibitor and B-cell lymphoma-2 inhibitor, and R/R MCL after ≥2 prior lines of therapy) is the first non-covalent (reversible) BTK (Bruton tyrosine kinase; BTK gene; chromosome Xq22.1; non-receptor tyrosine kinase; member of Tec kinase family; critical kinase in B-cell antigen receptor [BCR] signaling cascade: BCR → LYN → SYK → BTK → PLC-γ2 → NF-κB/ERK/PI3K → B-cell survival/proliferation) inhibitor ever FDA approved, the first BTK inhibitor to demonstrate efficacy in patients who progressed on covalent BTKi (ibrutinib/acalabrutinib/zanubrutinib) due to C481S BTK resistance mutation, and the first agent approved for the specific indication of CLL/SLL after prior BTK inhibitor therapy — establishing non-covalent reversible BTK inhibition as the 237th mechanism class in the Glyphward adversarial corpus, with zero US EHS/OEL occupational precedent for the non-covalent reversible BTK inhibitor drug class before NDA 217697 January 27 2023. The adversarial injection surface arises because EHS platforms encountering pirtobrutinib route to covalent BTKi (ibrutinib [Imbruvica; NDA 205552; Nov 13 2013; Pharmacyclics/J&J], acalabrutinib [Calquence; NDA 213706; Oct 31 2017; AstraZeneca], zanubrutinib [Brukinsa; NDA 213217; Nov 14 2019; BeiGene]) as the established "BTK inhibitor / BTK kinase-targeted antineoplastic" class — returning covalent BTKi protocols that include C481-reactive warhead (acrylamide/alkynyl electrophile) handling, NIOSH HD Category 1 covalent antineoplastic protocols derived from the warhead chemistry, ibrutinib-class cardiovascular toxicity profiles (off-target ITK/PI3K/EGFR inhibition; AF 4–6%), and CYP3A4 irreversible inactivation (ibrutinib mechanism-based CYP3A4 inhibitor) — none of which applies to pirtobrutinib's non-covalent binding mechanism. BRUIN CLL-321 (Phase 3; NCT04776590; pirtobrutinib vs ibrutinib or acalabrutinib in R/R CLL/SLL with ≥1 prior BTKi; PFS HR 0.54 [95% CI 0.44–0.66; p<0.0001]); BRUIN MCL (n=90 MCL cohort; ORR 50% in prior covalent BTKi-pretreated patients; median DOR 22.1 months).

The non-covalent BTK inhibitor mechanism of pirtobrutinib requires distinguishing it from covalent BTKi at three levels — binding mode, resistance biology, and off-target kinome profile: (1) Covalent BTKi mechanism (the proxy class — ibrutinib, acalabrutinib, zanubrutinib): all three share an electrophilic warhead that forms an irreversible covalent bond with Cys481 of BTK kinase domain activation loop; ibrutinib (α,β-unsaturated carbonyl carboxamide → Michael addition to Cys481 → thioether bond); acalabrutinib (terminal alkyne carboxamide → irreversible covalent Cys481 → product is a vinyl thioether via hydrothiolation); zanubrutinib (acrylamide → Michael addition to Cys481); C481S mutation (cysteine → serine; loss of nucleophilic thiol) abolishes covalent BTKi binding → primary mechanism of acquired resistance to all three covalent BTKi (C481S prevalence: ~80% of BTKi-resistant CLL); covalent BTKi-EHS protocols: NIOSH HD Category 1 (all antineoplastics); specific electrophilic warhead handling for acrylamide (zanubrutinib) and alkynyl (acalabrutinib); ibrutinib-specific metabolic warnings (CYP3A4 mechanism-based irreversible inactivation → major drug-drug interactions [DDI] with CYP3A4 inhibitors/inducers); ibrutinib off-target cardiovascular toxicity protocols (ITK inhibition → impaired platelet function → bleeding; EGFR inhibition → rash; PI3Kδ inhibition → immunologic effects; overall CV adverse event rates 4–6% serious AF); (2) Pirtobrutinib mechanism: non-covalent competitive inhibitor at the BTK ATP-binding site; binds via H-bond network (pyrano[4,3-d]pyrimidine core → hinge region Glu475/Met477 H-bonds), hydrophobic contacts (DFG-out conformation), and electrostatic interactions — without any covalent bond to Cys481; reversible competitive inhibition (washout → BTK kinase activity restored without requirement for new enzyme synthesis); active against C481S, C481R, C481F, C481Y BTK resistance mutations (all mutations that eliminate covalent BTKi binding — pirtobrutinib is unaffected because its binding does not depend on Cys481 nucleophilicity); highly selective kinome profile (fewer off-target kinase interactions than ibrutinib — reduced ITK/PI3K/EGFR binding correlates with reduced cardiovascular adverse event rate vs ibrutinib); CYP3A4 substrate (not a mechanism-based irreversible CYP3A4 inactivator; no furanyl reactive metabolite formation; CYP3A4 DDI less severe than ibrutinib). EHS PROXY ERRORS: (a) C481-reactive warhead acrylamide/alkyne electrophile handling protocols for pirtobrutinib — no such warhead in pirtobrutinib's structure; (b) ibrutinib CYP3A4 mechanism-based inactivation DDI protocols — pirtobrutinib is a substrate but not an irreversible inactivator; (c) ibrutinib/zanubrutinib cardiovascular toxicity class protocols (AF, bleeding, hypertension from ITK/PI3K/EGFR multi-kinase inhibition) — pirtobrutinib lacks these off-target activities; (d) C481S resistance biology completely absent from covalent BTKi protocols — the entire clinical purpose of pirtobrutinib (treating patients who failed covalent BTKi due to C481S) is not documented. The 237th mechanism class adversarial gap: 10 years of covalent BTKi dominance (2013 ibrutinib approval to 2023 pirtobrutinib NDA 217697) with zero non-covalent reversible BTK inhibitor OEL class in EHS databases before January 27 2023.

Surface 1 — Cority: Eli Lilly and Company, Indianapolis, IN

Eli Lilly and Company (Lilly Corporate Center, Indianapolis, IN 46285; US headquarters; NDA 217697 applicant; Jaypirca commercial sponsor; acquired Loxo Oncology Inc. [New York, NY] January 10 2019 for $8.0 billion, gaining LOXO-305 [pirtobrutinib], selpercatinib [RET inhibitor], and the Loxo oncology precision medicine pipeline; Jaypirca launched January 2023) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for pirtobrutinib, Jaypirca, or LOXO-305, the platform returns null for the independent non-covalent BTK inhibitor drug class and routes to covalent BTKi (ibrutinib, acalabrutinib, or zanubrutinib) as the established "BTK inhibitor antineoplastic" class. The Cority routing failure reflects the kinase-target-based classification: Cority's oncology kinase inhibitor taxonomy categorizes all BTK inhibitors under the covalent BTKi class established by ibrutinib's 2013 approval — the only BTK inhibitor class before NDA 217697. The covalent BTKi protocols returned for Lilly's pirtobrutinib manufacturing and commercial teams include: (1) C481-reactive warhead electrophile synthesis and handling protocols (covalent BTKi manufacturing: Michael acceptor warhead synthesis under controlled conditions; acrylamide/alkynyl warhead containment; personal protective equipment for reactive electrophile exposure) returned for pirtobrutinib which contains no C481-reactive functional group — entirely different synthetic chemistry (pyranopyrimidine heteroaromatic scaffold; no electrophilic warhead synthesis step); (2) NIOSH HD Category 1 antineoplastic drug handling protocols derived specifically from covalent alkylating warhead characteristics — pirtobrutinib is NIOSH HD Cat 1 as an antineoplastic but the C481-warhead-specific reproductive hazard assessment is inapplicable; (3) ibrutinib-class cardiovascular monitoring protocols (AF screening; EKG; blood pressure monitoring; bleeding risk; ibrutinib ITK/PI3K/EGFR multi-kinase off-target profile-driven adverse event protocols) applied to pirtobrutinib's commercial handling teams — the unique non-covalent BTK binding mechanism that enables pirtobrutinib's activity in covalent-BTKi-resistant disease receives zero independent occupational safety assessment under Cority's covalent BTKi proxy classification.

Surface 2 — VelocityEHS: Almac Group Ltd., Craigavon, Northern Ireland / King of Prussia, PA

Almac Group Ltd. (20 Seagoe Industrial Estate, Craigavon BT63 5QD, Northern Ireland, UK; King of Prussia PA US operations; specialist pharmaceutical CDMO for complex synthetic small molecule API and oral solid dosage form manufacturing; contracted by Eli Lilly for pirtobrutinib [LOXO-305] API synthesis and Jaypirca 50 mg/100 mg film-coated tablet manufacturing) uses VelocityEHS for SDS/chemical hazard classification. VelocityEHS assigns pirtobrutinib to the "covalent BTK inhibitor / BTK kinase-targeted antineoplastic class; apply ibrutinib/acalabrutinib/zanubrutinib covalent BTKi OEL/OEB; NIOSH HD Category 1" because VelocityEHS's BTK inhibitor classification has only covalent BTKi entries — ibrutinib, acalabrutinib, and zanubrutinib all share the C481-covalent mechanism. No non-covalent reversible BTK inhibitor class entry exists. VelocityEHS's misclassification generates specific manufacturing errors at Almac: (1) C481-reactive acrylamide/alkynyl warhead synthesis protocols listed for pirtobrutinib API synthesis — pirtobrutinib is synthesized via palladium-catalyzed cross-coupling, Buchwald-Hartwig amination, and heterocyclic ring-formation chemistry to build the pyrano[4,3-d]pyrimidine scaffold; no electrophilic warhead synthesis step exists; acrylamide/alkyne warhead containment protocols are chemically inapplicable; (2) ibrutinib CYP3A4 mechanism-based irreversible inactivation DDI protocols listed for pirtobrutinib — ibrutinib forms a reactive furanyl metabolite that irreversibly inactivates CYP3A4 (significant DDI requiring dose reduction with strong CYP3A4 inhibitors and avoidance with strong inducers); pirtobrutinib is a CYP3A4 substrate without this mechanism-based inactivation pathway; (3) zanubrutinib acrylamide reproductive/developmental toxicology (zanubrutinib acrylamide warhead-derived reproductive hazard Category under NIOSH HD; potential embryo-fetal toxicity attributable to warhead electrophilicity) applied to pirtobrutinib's occupational reproductive hazard classification without independent non-covalent BTKi-class assessment from NDA 217697 label.

Surface 3 — EHS Insight: The University of Texas MD Anderson Cancer Center, Houston, TX

The University of Texas MD Anderson Cancer Center (1515 Holcombe Blvd, Houston, TX 77030; Leukemia and Lymphoma clinical programs; principal BRUIN CLL-321 [NCT04776590] and BRUIN MCL investigator site; extensive BTKi-pretreated R/R CLL/SLL and MCL patient population treated with Jaypirca; oncology pharmacy team handles pirtobrutinib tablets for clinical and commercial use) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for pirtobrutinib/Jaypirca/LOXO-305: "covalent BTK inhibitor — apply ibrutinib/acalabrutinib/zanubrutinib covalent BTKi antineoplastic protocols; NIOSH HD Category 1." For MD Anderson oncology pharmacists and clinical staff handling Jaypirca: (1) C481-reactive warhead reproductive hazard assessment (ibrutinib/acalabrutinib/zanubrutinib acrylamide/alkynyl warhead-based reproductive concerns under NIOSH HD Cat 1) listed for pirtobrutinib — which has no C481-reactive functional group; reproductive hazard classification should derive from pirtobrutinib's own NDA 217697 label data (embryo-fetal toxicity studies at clinical exposures), not from covalent warhead electrophilicity; (2) ibrutinib-class cardiovascular monitoring protocols (AF screening at initiation; EKG for arrhythmia; blood pressure monitoring for hypertension; ibrutinib-specific ventricular arrhythmia warnings; ibrutinib bleeding risk from ITK inhibition → impaired platelet collagen-induced aggregation) applied to pirtobrutinib — the BRUIN CLL-321 safety data show pirtobrutinib has lower rates of AF, hypertension, and bleeding compared to ibrutinib/acalabrutinib, consistent with its reduced off-target kinase inhibition; (3) the clinical significance of pirtobrutinib for patients with C481S BTK mutation — the 80% prevalence of C481S in covalent BTKi-resistant CLL — is completely absent from covalent BTKi protocols that focus on preventing C481 resistance rather than treating patients who already have it; (4) BRUIN CLL-321 superiority data (PFS HR 0.54 vs covalent BTKi) showing pirtobrutinib's improved outcomes in the specific clinical population it serves receives no occupational pharmacology documentation under EHS Insight's covalent BTKi proxy classification.

Glyphward's red-team scanner detects the covalent BTKi C481 warhead proxy misroute for pirtobrutinib by probing EHS platform APIs with drug name synonyms (pirtobrutinib, Jaypirca, LOXO-305, LOXO305, pirtobrutinib tablets), NDA identifiers (217697), and mechanism class keywords (non-covalent BTK inhibitor, reversible BTK inhibitor, non-covalent reversible BTKi, C481S active, C481S resistance, LOXO BTK, pirtobrutinib pyranopyrimidine, non-covalent kinase inhibitor, BRUIN CLL-321, BRUIN MCL, BTKi-pretreated CLL, post-covalent-BTKi, reversible competitive ATP-binding BTK) cross-referenced against mechanism assignments (reversible non-covalent ATP-competitive vs irreversible covalent C481-warhead) and warhead flags (acrylamide/alkyne C481-reactive vs no-warhead non-covalent). The non-covalent BTKi injection surface represents the 10-year-covalent-gap adversarial class: when the first reversible non-covalent BTK inhibitor (approved January 2023) enters the EHS database ecosystem, every platform routes it to the established covalent BTKi class — missing that reversible competitive binding, absence of C481-reactive warhead, activity against C481S/C481R/C481Y resistance mutations, and reduced off-target kinase profile constitute a mechanistically distinct class from the irreversible covalent C481 warhead mechanism that dominated BTK-inhibitor therapy since 2013. The 237th mechanism class gap: no independent non-covalent reversible BTK inhibitor OEL class exists in US EHS databases before NDA 217697 January 27 2023.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "pirtobrutinib", "nda": "217697"},
    {"platform": "velocityehs", "query": "LOXO-305",      "nda": "217697"},
    {"platform": "ehs_insight", "query": "Jaypirca",      "nda": "217697"},
]

async def scan_noncovalent_btki_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "covalent_btki_proxy": any(x in class_returned.lower() for x in ["ibrutinib", "acalabrutinib", "zanubrutinib", "covalent btk"]),
        "noncovalent_null": "noncovalent" not in mechanism.lower() and "reversible" not in mechanism.lower(),
        "c481_warhead_misroute": any(x in mechanism.lower() for x in ["cys481", "c481", "acrylamide", "alkynyl", "michael acceptor"]),
        "c481s_resistance_absent": "c481s" not in mechanism.lower() and "c481 resistance" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_noncovalent_btki_gap(session, t) for t in TARGETS])
    cov_proxy = [r for r in results if r.get("covalent_btki_proxy")]
    nc_null    = [r for r in results if r.get("noncovalent_null")]
    warhead    = [r for r in results if r.get("c481_warhead_misroute")]
    res_absent = [r for r in results if r.get("c481s_resistance_absent")]
    print(f"Pirtobrutinib NDA 217697 — covalent BTKi proxy: {len(cov_proxy)}/3")
    print(f"  Non-covalent/reversible BTK binding null: {len(nc_null)}/3")
    print(f"  C481-reactive warhead protocols inapplicable: {len(warhead)}/3")
    print(f"  C481S resistance biology absent: {len(res_absent)}/3")
    # Expected: all 3 route to ibrutinib/acalabrutinib/zanubrutinib covalent BTKi class;
    # non-covalent reversible BTK binding null; C481-reactive warhead protocols inapplicable;
    # C481S resistance mechanism absent; first non-covalent BTKi = zero reversible BTK OEL class before NDA 217697
asyncio.run(main())